Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 50, Issue SUPPL. 2, 2009, Pages 9-15

  Milone, Jorge H ^a   Enrico, Alicia ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

ALL; Philadelphia chromosome; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; BOSUTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; NILOTINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DONOR; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEVER; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; STEM CELL; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; HUMANS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 73849107115     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903370395     Document Type: Review

References (44)

1. World Health Organization Classification of Tumor. Pathology and Genetic. In: Jaffe ES, Nancy LH, Harold S, James W, editors. Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
2. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR-ABL genes and leukemic phenotype from molecular mechanisms to clinical correlations. Oncogene 2002;21:8652-8667.
3. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003;98:1337-1354.
4. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL). Analysis of GIMEMA 0496 protocol. Blood 2005;105: 3434-3441.
5. Huettner C, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000;4:57-60.
6. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:118-145.
7. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006. (Pubitemid 30180646)
8. Armstrong SA, Thomas LA. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306-6315.
9. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536-1543.
10. Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 2001;67: 73-83.
11. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia characteristic factor and treatment outcome. Hematol Cell Ther 1998;40:119-128.
12. Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002;87:154-166.
13. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 1992;64: 97-100.
14. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992;80:2983-2990.
15. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-2366.
16. Forman SJ, O'Donnell MR, Nademanee AP, et al. Bone marrow transplantation for patients with Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood 1987; 70:587-588.
17. Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosomepositive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999;13:2053-2058.
18. Dahlke J, Kroger N, Zabelina T, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006;37:155-163.
19. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia:no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22:2816-2825.
20. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006. (Pubitemid 30180646)
21. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369:1947-1954.
22. Marks DI, Aversa F, Lazarus HM. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 2006;38:467-475.
23. Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003;88:555-560.
24. Ottmann OG, Labopin M, Ruutu T, et al. Allogeneic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in recent years: a retrospective EBMT analysis of patients transplanted in first remission. Bone Marrow Transpl 2009;43 (Supp 1):O281.
25. Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005;129:35-44.
26. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogenic transplantation for very high risk childhood acute lymphoblastic leukaemia in first complete remission comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635-642.
27. Hout R, Tavernier E, Le QH, et al. Philadelphia chromosome positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology 2004;9: 369-376.
28. Goekbuget N, de Wit M, Gerhardt A, et al. Results of shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia (ALL). Blood 2000;96: 3104a.
29. Huguet F, Boissel N, Dombret H. Acute lymphoblastic leukemia in adolescents and young adults: is the treatment paradigm changing? ASCO Educational Book 2009;27:360-370.
30. Druker B, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
31. Ottmman O, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:118-122.
32. Hofmann WK, Komor M, Hoelzer D, Ottmann OG. Mechanisms of resistance to STI571 (imatinib) in Philadelphiachromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004;45:655-656.
33. Pfeifer H, Brueck P, Wassmann B, et al. BCR-ABL mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) receiving Glivec-based therapy [abstract]. Presentado en: 10th Congress of the European Hematology Association; 2-5 Junio 2005; Estocolmo, Suecia. Abstract 431.
34. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome positive acute lymphocytic leukemia with hyper CVAD and imatinib mesylate. Blood 2004; 103:4396-4407.
35. Yamada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR ABL positive acute lymphoblastic leukemia. A Phase II study by the Japan Adult leukemia Study Group. J Clin Oncol 2006;24: 460-466.
36. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MDR positive Philadelphia positive acute lymphoblastic leukemia Ph positive ALL. Blood 2005;106:458-463.
37. Wassmann B, Goekbuget N, Pfeifer H, et al. Stem cell transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in first complete remission after Imatinib-based induction therapy. Results of GMALL trial. Hematologica 2005;90(Suppl. 2):O797, 317.
38. Ottmann O, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front line treatment of elderly patients with Philadelphia chromosome positive acute lymphoblastic leukemia Ph ALL. Cancer 2007;109:2068-2076.
39. Sawyer C, Kantarjian H, Shah N, et al. Dasatinib (BMS- 354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Who are resistant or intolerant to imatinib: update of a Phase I Study [Oral Sessions]. Blood 2005;106:(Abstract 38).
40. Ottman O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymhpoblastica leukemia with resistance or intolerance to imatinib: interim results of phase 2 study. Blood 2007;110:2309-2315.
41. Ravandi F, Faderl S, Thomas D, et al. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). J Clin Oncol 2008;26:(Suppl. 15):7020.
42. Porkka K, Simonsson B, Dombret H, et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2 year follow up data from START-L (CA 180015) [Poster Session]. Blood 2007;110:(Abstract 2810).
43. Melo J, Chuah CH. Nove agents in CML therapy: tyrosine kinase inhibitor and beyond. Hematology; 2008;1:427-435.
44. Foà R, Vitale A, Guarini A, et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL 1205 Study [Oral Session]. Blood 2008;112:(Abstract 305).